STANDARD BIOTOOLS INC.

Standard BioTools, Inc. provides life science tools, including instrumentation, consumables, and services, to biomedical researchers. The company's solutions generate high-quality data for early discovery, translational, and clinical research, with advanced technologies in proteomics and genomics. These tools help scientists gain biological insights and accelerate discoveries across therapeutic areas such as immunology, oncology, neuroscience, and cardiometabolic diseases. On June 22, 2025, Standard BioTools entered into a Stock Purchase Agreement with Illumina, which closed on January 30, 2026. Under this agreement, Illumina acquired all equity interests of SomaLogic, Inc., Sengenics Corporation LLC, and Sengenics Corporation Pte Ltd (collectively, the "Disposed Entities"). These entities operated the company's aptamer-based and functional proteomics business, including KREX, Single SOMAmer, translational, and diagnostic assays (collectively, the "SomaScan Business"). The SomaScan Business has been classified as held-for-sale and a discontinued operation under generally accepted accounting principles in the United States ("GAAP"). The company retained its mass cytometry and microfluidics businesses. The description of the business in this Annual Report on Form 10-K relates solely to its continuing operations. Standard BioTools' platforms offer multi-omic capabilities, supporting innovation and drug development by unlocking biological information across plasma, single-cell, and spatial proteomics, as well as genomic analyses.